Market closedNon-fractional
Nautilus Biotechnolgy/NAUT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Nautilus Biotechnolgy
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Ticker
NAUT
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Seattle, United States
Employees
163
Website
www.nautilus.bio
NAUT Metrics
BasicAdvanced
$288M
Market cap
-
P/E ratio
-$0.54
EPS
1.00
Beta
-
Dividend rate
Price and volume
Market cap
$288M
Beta
1
Financial strength
Current ratio
20.093
Quick ratio
19.688
Long term debt to equity
12.003
Total debt to equity
13.476
Management effectiveness
Return on assets (TTM)
-15.70%
Return on equity (TTM)
-24.38%
Valuation
Price to book
1.16
Price to tangible book (TTM)
1.16
Price to free cash flow (TTM)
-4.972
Growth
Earnings per share change (TTM)
17.66%
3-year earnings per share growth
-3.17%
What the Analysts think about NAUT
Analyst Ratings
Majority rating from 4 analysts.
NAUT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$19M
10.00%
Profit margin
0.00%
NaN%
NAUT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.13
-$0.13
-$0.14
-$0.15
-
Expected
-$0.15
-$0.17
-$0.15
-$0.16
-$0.17
Surprise
-13.33%
-22.39%
-3.45%
-7.69%
-
NAUT News
AllArticlesVideos
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
GlobeNewsWire·2 months ago
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nautilus Biotechnolgy stock?
Nautilus Biotechnolgy (NAUT) has a market cap of $288M as of July 06, 2024.
What is the P/E ratio for Nautilus Biotechnolgy stock?
The price to earnings (P/E) ratio for Nautilus Biotechnolgy (NAUT) stock is 0 as of July 06, 2024.
Does Nautilus Biotechnolgy stock pay dividends?
No, Nautilus Biotechnolgy (NAUT) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Nautilus Biotechnolgy dividend payment date?
Nautilus Biotechnolgy (NAUT) stock does not pay dividends to its shareholders.
What is the beta indicator for Nautilus Biotechnolgy?
Nautilus Biotechnolgy (NAUT) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Nautilus Biotechnolgy stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.